Introduction: Inflatable penile prosthesis has become an important treatment modality for men with erectile dysfunction that is refractory to medication. Despite high levels of patient satisfaction following inflatable penile prosthesis placement and inflatable penile prosthesis coverage by Medicare, coverage by commercial insurance providers is unknown. The purpose of this study was to determine the coverage of inflatable penile prosthesis by commercial insurance providers.
Since the early 1970s the inflatable penile prosthesis has been available for the treatment of erectile dysfunction that is refractory to treatment with oral and injectable medications. 1 Thanks to advances in IPP technology and surgical techniques, patient satisfaction after IPP has been reported to be higher than that of patients treated with oral sildenafil or intravenous prostaglandin E1. 2 Tefilli et al found that patients reported decreased feelings of sadness, depression, anxiety, anger, frustration and embarrassment related to sexual activity after IPP implantation. 3 This same study also showed that there was an increase in the frequency of sexual activity and an improvement in satisfaction with sex life. Interestingly, a 2014 study showed that use of IPP increased among patients with ED older than 65 years between 2001 and 2010, but decreased in the ED population overall. 4 A handful of factors may represent barriers to utilization of IPP, not the least of which is cost. The out-of-pocket cost of IPP is between $10,000 and $20,000 without insurance. 5 The increase in utilization by the population older than 65 years is largely attributable to the fact that IPP is a covered benefit by Medicare. However, coverage of IPP by commercial insurance providers is more difficult to predict, likely contributing to the overall decrease in use. In this study we identified trends in insurance coverage of IPP among patients at the University of Miami.
Materials and Methods
Following institutional review board approval (IRB No. 20170849) we retrospectively reviewed all billing records at the University of Miami between January 2016 and December 2017 based on CPT code 54405. Based on this search we were able to identify the insurers for all men who received an IPP at the University of Miami during the specified period. We also identified the insurers of men for whom an IPP claim was submitted but was excluded during the same time frame by searching a manually maintained file of denials and exclusions during the specified time. Indications for IPP were identified for all patients in the population via medical record review. 
Discussion
IPP has proven to be an effective option for men with ED in whom primary therapy has failed. However, its prohibitive outof-pocket cost makes insurance coverage a necessity for most men seeking this treatment. In this study we sought to determine how often men are able to receive IPP coverage at our tertiary center and which commercial insurers tend to provide coverage for this surgery. We found that Medicare is the single largest coverer of IPP among our study population. In addition, a significant proportion of men in our population with commercial insurance who desire IPP and have medically necessary indications are not able to obtain IPP. This raises questions about whether commercial insurers should be mandated to cover these costs, particularly if deemed medically necessary by a physician. As price remains a significant barrier to access for men desiring IPP, lack of coverage by commercial insurance providers creates an insurmountable barrier for these patients, who will likely be deprived of a procedure that addresses an individual right, based on the WHO consensus statement on erectile dysfunction. Our finding that PPO plans approve IPP at a rate similar to HMO plans, 60% and 50%, respectively, only muddles the picture of which commercial insurer and policy type is best for men seeking IPP. The number of men facing these commercial insurance practices is undoubtedly not trivial, given that 35% of men may progress to second line treatment options for ED. 6 It also reflects an underlying gender bias that is highlighted in a 2017 study investigating the degree of transparency surrounding policies of more than 80 popular insurance plans regarding ED and hypogonadism, using breast reconstruction following mastectomy as a control. The authors found publicly available policies for advanced ED treatment in only 39% of plans examined while breast reconstruction policies were publicly available for 94%. 7 We believe that these policies unfairly force men to wait until they reach age 65 to be able to resume sexual activity, which not only adversely impacts quality of life for these men, but pushes the responsibility for health care costs back to government agencies. This is reflected by the increasing trend in IPP use among the population older than 65 years, for whom IPP is covered by Medicare, and decreased use overall, suggesting that access to IPP coverage may have a role in use. To our knowledge this study is the first to assess coverage of IPP by specific commercial insurance providers at a tertiary academic center. Our study adds to the existing literature that has assessed the demographics of men receiving an IPP with commercial insurance coverage and has investigated the transparency of commercial insurance plans regarding coverage of advanced ED treatment. 2, 7 While the findings reported here are the experience in Miami and South Florida, we encourage other institutions to perform similar analyses to compare findings regionally, particularly pertaining to the high rate of commercial exclusions of IPP coverage vs denials of coverage. Our study has several limitations. It is likely that our Medicaid population is underrepresented given that IPP is a known Medicaid exclusion. Additional Medicaid recipients were likely not captured in our manually maintained file of exclusions as claims were never submitted on their behalf. We also did not include malleable implant surgeries performed during the study period due to the exceedingly low volume but instead limited our data to CPT code 54405. Additional limitations include small sample size.
Conclusions
The majority of IPP insurance coverage in the Miami and South Florida region is provided by Medicare. However, a large proportion of men with ED who desire IPP are unable to obtain it due to exclusions in their commercial insurance coverage. It is imperative that we improve IPP access by increasing transparency into which commercial insurers are the most likely to provide coverage for IPP. Urologists should familiarize themselves with the common commercial insurance companies among their study population that provide coverage for IPP in order to counsel their patients on this topic.
Editorial Commentary
In this important study Masterson et al looked at insurance coverage for inflatable penile prosthesis implant surgery at a tertiary care center in southern Florida. They found that approximately half of their patients with commercial insurance were unable to get an IPP, mostly due to insurance exclusions. Insurance coverage is an issue with phosphodiesterase type 5 inhibitors, vacuum erection devices and penile injection therapy as well. It is unfortunate that access to these effective male ED therapies has significant hurdles despite evidence showing that treatment leads to satisfactory sexual improvement, enhanced quality of life for the patient and his partner, and decreased comorbidities. The lack of transparency in male sexual health coverage along with the high rate of noncoverage of IPPs are areas that need reform. Reconstructive surgery coverage for women after mastectomy would be a fair comparator.
